Whole-Body Counting and In Vivo Bioassay

Introduction

In vivo bioassay measures radioactivity inside the body directly: a shielded detector counts the photons that escape the body and converts them, through calibration and biokinetic modeling, into an estimate of internal dose. It is the most direct way to answer the question a radiation safety officer dreads — did a worker actually take something in, and how much? — for radionuclides that emit penetrating photons.

Internal dose is fundamentally harder to manage than external dose. You cannot read it off a badge, you cannot shield it after the fact, and the intake may have happened days before anyone suspects it. A bioassay program exists to close that gap: to detect intakes, quantify them, assign committed dose, and demonstrate compliance with occupational limits. ^{1, 3}

In vivo counting — whole-body, lung, thyroid, bone, and wound counting — is one of the two pillars of that program, the other being in vitro analysis of excreta. This guide explains the detectors and geometries, the minimum detectable activity (MDA) math that determines how sensitive a program can be, the phantom calibration that makes the numbers traceable, and how a measured body burden becomes a committed effective dose. DRPS supports internal-dosimetry and bioassay programs through radiation safety officer consulting and medical physicist consulting across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

In vivo versus in vitro bioassay

Bioassay is the determination of the kind, quantity, location, and retention of radionuclides in the body, either by direct measurement (in vivo) or by analysis of material excreted or removed from the body (in vitro). ¹ The two approaches are complementary:

In vivo bioassay uses external detectors to count photons escaping the body. It works for radionuclides that emit penetrating gamma rays or, with specialized detectors, low-energy photons and characteristic x-rays. It gives a direct body or organ content with no waiting for sample collection.
In vitro bioassay measures activity in urine, feces, or other samples. It is essential for pure beta emitters (for example, tritium or strontium-90) and alpha emitters that cannot be detected externally, and it supports intake estimates through excretion modeling.

A mature program often uses both. For the excreta side and the radioiodine worker program specifically, see Thyroid bioassay for I-131 workers.

When monitoring is required

Under the NRC occupational dose framework, individual monitoring for internal exposure is required when a worker is likely to receive an intake exceeding 10 percent of the applicable annual limit on intake (ALI) in a year. ^{3, 5} The bioassay program is how a facility detects and quantifies intakes and demonstrates whether that threshold is crossed. A program built only for external dose — film badges and electronic dosimeters — says nothing about an inhaled or ingested radionuclide. For the external-dose companion, see NRC occupational dose limits (Part 20).

Key Technical Principles

Detectors and counting geometries

The detector and geometry are chosen to match the radionuclide's photon energy and its expected distribution in the body. A uniformly distributed whole-body contaminant, a lung deposit of inhaled particles, and a thyroid uptake of radioiodine each require a different measurement. ^{1, 2}

Measurement	Typical detector	Target radionuclides (photon energy)	Distribution assumed
Whole-body counting	Large NaI(Tl) or HPGe in a shielded room/chair	Cs-137 (662 keV), Co-60 (1.17/1.33 MeV), K-40 (1.46 MeV)	Uniform whole-body
Lung (chest) counting	Thin HPGe or phoswich	Am-241 (60 keV), transuranic L x-rays (about 13–20 keV)	Lung deposition
Thyroid counting	Collimated NaI(Tl)	I-131 (364 keV), I-125 (27–35 keV)	Thyroid organ
Bone/skeletal counting	Low-energy HPGe (for example, over the knee)	Am-241 in bone (60 keV)	Skeletal
Wound counting	Collimated low-energy detector	Localized transuranics	Localized deposit

NaI detectors offer high efficiency and are efficient for survey-type whole-body counting; HPGe detectors offer far better energy resolution, which lets a counter separate and identify specific radionuclides in a mixed spectrum. Low-energy photon emitters such as americium-241 and the transuranics are the hardest case, because their 13–60 keV photons are heavily attenuated by overlying tissue; these measurements use thin, low-energy detectors and careful chest-wall-thickness correction. A published whole-body counting laboratory reported a minimum detectable activity of about 7 Bq for americium-241 in the knee with a 1800-second count using low-energy germanium detectors. ⁹

Background, shielding, and the MDA equation

The sensitivity of any in vivo measurement is set by the background count rate and the counting time, captured quantitatively in the minimum detectable activity. The MDA is the smallest activity that can be reliably distinguished from background. Using the Currie formulation for paired sample-and-background counting, the net-count detection limit is: ⁷

MDA_{counts} = 2.71 + 4.65 B

where $B$ is the background counts accumulated in the same counting interval as the sample. Converting counts to activity requires the overall counting efficiency $ε$ (counts per second per becquerel, folding in detector efficiency, geometry, and photon yield) and the counting time $t$ in seconds:

MDA (Bq) = \frac{2.71 + 4.65 B}{ε t}

As a worked example, suppose a counter accumulates $B = 900$ background counts in $t = 600$ s, with an overall counting efficiency of $ε = 0.015$ cps/Bq (1.5%):

MDA_{counts} = 2.71 + 4.65 900 = 2.71 + 4.65 (30) = 142.2 counts

MDA (Bq) = \frac{142.2}{0.015 \times 600} = \frac{142.2}{9.0} \approx 15.8 Bq

This is why whole-body counters live inside thick steel or lead shielded rooms: halving the background $B$ reduces the MDA by a factor of about $2$ , and longer counting and higher efficiency both drive the MDA down. The ANSI/HPS N13.30 standard specifies how MDA, bias, and precision are to be determined and what performance a bioassay service laboratory must meet. ²

Calibration with anthropomorphic phantoms

A whole-body counter reports counts; turning counts into body activity requires a calibration that ties the count rate to a known activity in a realistic body geometry. This is done with anthropomorphic phantoms loaded with traceable radionuclide standards: a whole-body phantom (for example, a set of fluid-filled containers or a brick-style phantom) for uniform distributions, a chest phantom with simulated lungs for inhalation cases, and a neck-thyroid phantom for radioiodine. ^{1, 9}

The counting efficiency is the measured count rate divided by the known phantom activity at the relevant photon energy. Because attenuation depends on body size, efficiency must account for the subject's physique (chest-wall thickness especially matters for low-energy lung counting). Traceability to a national standards laboratory is what makes the final dose defensible in an inspection or a dose-reconstruction case. Mobile and fixed bioassay laboratories alike are built around this phantom-calibration step, with detection limits converted to minimum committed effective doses to confirm the system is fit for its monitoring purpose. ⁸

From body burden to committed effective dose

A measured body or organ activity is not yet a dose. The interpretation chain is:

Measure the body or organ activity $A_{meas}$ (Bq) with the calibrated counter.
Estimate the intake $I$ (Bq) by applying a biokinetic retention model for the radionuclide, the route of intake, and the time since exposure. ⁴
Compute committed effective dose by multiplying the intake by the committed effective dose coefficient $e (50)$ (Sv/Bq) published by the ICRP:

E (50) = I \times e (50)

For example, if the interpretation yields an ingested intake of $I = 1000$ Bq of iodine-131, and the ICRP adult ingestion committed effective dose coefficient for I-131 is approximately $e (50) = 2.2 \times 1 0^{- 8}$ Sv/Bq: ¹⁰

E (50) = 1000 Bq \times 2.2 \times 1 0^{- 8} Sv/Bq = 2.2 \times 1 0^{- 5} Sv = 0.022 mSv

The committed effective dose is the 50-year integrated dose from that single intake, and it is what is compared against the occupational limit. The dose coefficients and the underlying biokinetic and dosimetric models are maintained in the ICRP Occupational Intakes of Radionuclides series. ⁴

Clinical Impact

What a bioassay program protects

In a medical setting, internal exposure risk concentrates in a few activities: radioiodine therapy and radiopharmacy work (I-131, I-125), PET radiopharmaceutical production and handling, and radiopharmaceutical-therapy programs using isotopes such as Lu-177 or Ra-223. A nuclear pharmacist who repeatedly handles I-131 capsules, or a technologist who manages a radioiodine therapy patient, can inhale or ingest activity, and a thyroid count is the direct way to detect it. ¹

A bioassay program turns "we think the ventilation was adequate" into "we measured a thyroid burden below our MDA, so the committed dose is below our recording level." That is the difference between a defensible ALARA program and a hopeful one. For the workflow context, see Radiopharmaceutical extravasation dosimetry and Respiratory protection for airborne radioactivity.

Baseline and routine counting

Baseline counts establish a worker's body content before they begin work with a radionuclide, so a later count can be interpreted against their own background (K-40 is always present; prior medical administrations can linger).
Routine counts at a defined frequency detect chronic low-level intakes.
Special (triggered) counts follow a known or suspected incident — a spill, a failed fume hood, a contaminated wound — and should be done promptly, because retention falls with time and a delayed count underestimates the intake.

The sensitivity trap

If a program's MDA is higher than the activity corresponding to a dose of regulatory or ALARA concern, a "not detected" result is meaningless — it cannot prove the dose was low. Designing the counting time, shielding, and detector so the MDA sits comfortably below the dose of concern is the core physics task of setting up a bioassay program. ^{2, 7}

Practical Optimization Tips

1. Design the MDA to the dose of concern

Work backward: decide the committed dose you need to be able to detect, convert it to a body or organ activity, and then choose counting time, detector, and shielding so the MDA is below that. Do not accept the vendor's nominal MDA without checking it against your own background. ^{2, 7}

2. Count promptly after a suspected intake

Retention and excretion reduce measurable activity over time. A thyroid count done the same day after a suspected I-131 intake is far more informative than one done a week later. Build a rapid-response path into the program.

3. Take and keep baselines

A pre-employment or pre-task baseline count makes every later count interpretable. Store the spectra, not just the numbers.

4. Keep calibration traceable and current

Use anthropomorphic phantoms with traceable standards, recalibrate on a schedule, and match the phantom geometry to the expected distribution. Account for body size in low-energy lung counting. ^{1, 9}

5. Document the full chain

Record the measured activity, the biokinetic model and assumptions used, the intake estimate, the dose coefficient, and the resulting committed effective dose. The defensibility of the dose is the defensibility of the chain. ⁴

Common pitfalls to avoid

An MDA above the dose of concern, making "not detected" results meaningless.
Delaying a triggered count, which underestimates the intake.
Using in vivo counting for a pure beta or alpha emitter that cannot be detected externally — that case needs in vitro bioassay.
Ignoring body-size attenuation in low-energy lung and bone counting.
Losing traceability by calibrating against a non-traceable source or the wrong geometry.

Regulatory Considerations

A bioassay program must be documented against the occupational-dose rules and the accepted technical standards for internal dosimetry. The governing frameworks are: ^{2, 3, 4, 5, 6}

10 CFR 20.1502 — requires individual monitoring of internal occupational dose when an intake is likely to exceed 10 percent of the applicable ALI in a year. ³
NRC Regulatory Guide 8.9 — acceptable concepts, models, equations, and assumptions for a bioassay program, including how to relate measurements to intake and dose. ⁵
NRC Regulatory Guide 8.20 — application of bioassay for iodine-125 and iodine-131, directly relevant to medical radioiodine programs. ⁶
ANSI/HPS N13.30-2011 (R2017) — performance criteria for radiobioassay, defining MDA determination, bias, precision, and service-laboratory quality requirements. ²
NCRP Report No. 87 — foundational guidance on the use of bioassay procedures for assessing internal radionuclide deposition. ¹
ICRP Publication 130 (Occupational Intakes of Radionuclides) — current biokinetic and dosimetric models and committed effective dose coefficients. ⁴

Agreement States administer equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that regulate radioactive-material use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility should connect its bioassay and internal-dosimetry program to its radiation safety officer consulting, radioactive material license support, and radiation safety training so the monitoring threshold, counting frequency, and dose-assessment method are written into the program and defensible at inspection. For the program-level audit context, see Annual radiation protection program audit.

Frequently Asked Questions (FAQs)

What is in vivo bioassay, and how is it different from in vitro bioassay?

In vivo bioassay measures radioactivity inside the body directly, by detecting the photons that escape the body with an external detector — whole-body, lung, thyroid, or wound counting. In vitro bioassay instead measures radioactivity in a biological sample taken from the body, such as urine or feces. In vivo works best for radionuclides that emit penetrating photons; in vitro is needed for pure beta or alpha emitters that cannot be detected externally.

What is minimum detectable activity, and why does it matter?

Minimum detectable activity (MDA) is the smallest amount of a radionuclide a counting system can reliably distinguish from background for a given counting time. It sets the sensitivity of a bioassay program: if the MDA for a radionuclide is above the activity that would correspond to a dose of regulatory concern, the measurement cannot demonstrate compliance. MDA improves with longer counting, higher detector efficiency, and lower background (more shielding).

What detectors are used for whole-body counting?

Whole-body counters typically use large sodium iodide (NaI) scintillation detectors or high-purity germanium (HPGe) detectors inside a heavily shielded room or chair to reduce background. NaI offers high efficiency; HPGe offers superior energy resolution for identifying specific radionuclides. Lung counting for low-energy photon emitters such as transuranics uses thin germanium or phoswich detectors, and thyroid counting for radioiodine uses a collimated NaI detector.

How is a whole-body counter calibrated?

Calibration uses anthropomorphic phantoms containing known activities of traceable radionuclide standards, positioned to mimic the distribution being measured — a whole-body phantom for uniformly distributed activity, a chest phantom for lung deposition, or a neck phantom for thyroid. The measured count rate per unit activity gives the counting efficiency, which converts future patient counts into body activity.

How is committed effective dose obtained from a bioassay measurement?

The measured body or organ activity is interpreted through a biokinetic model to estimate the intake, accounting for the time since exposure and the route. The intake is then multiplied by the committed effective dose coefficient for that radionuclide and intake route, published by the ICRP, to obtain the committed effective dose. The result is what is compared against occupational dose limits.

When is internal dose monitoring required?

Under the NRC framework, individual monitoring for internal dose is required when a worker is likely to receive, in a year, an intake exceeding 10 percent of the applicable annual limit on intake. Facilities establish bioassay programs — in vivo counting, in vitro sampling, or both — to detect and quantify intakes and to demonstrate that this threshold is or is not exceeded.

Which radionuclides are best suited to whole-body or thyroid counting?

Radionuclides emitting penetrating gamma rays are best suited to external counting: cesium-137, cobalt-60, and similar fission and activation products for whole-body counting, and iodine-131 or iodine-125 for thyroid counting. Low-energy photon emitters such as americium-241 and some transuranics require specialized low-energy lung or bone counters, while pure beta and alpha emitters generally require in vitro bioassay.

Key Takeaways

In vivo bioassay measures internal activity directly. It counts photons escaping the body and converts them to body or organ activity, then to dose.
MDA sets the whole program's sensitivity. The Currie formula ties detection limit to background and counting time; shielding and longer counts drive it down.
Detector and geometry must match the radionuclide. NaI or HPGe for whole-body, thin low-energy detectors for transuranic lung counting, collimated NaI for thyroid.
Calibration must be traceable. Anthropomorphic phantoms with traceable standards turn counts into defensible activity, with body-size attenuation accounted for.
Dose comes from a modeled chain. Measured activity leads to an intake through a biokinetic model, and intake times the ICRP dose coefficient gives committed effective dose.
Count promptly and keep baselines. Retention falls with time, so triggered counts must be fast, and baselines make every later count interpretable.

Conclusion

Internal dose is the part of a radiation safety program that cannot be managed by badges and shielding alone. A bioassay program — in vivo counting backed by in vitro sampling where needed — is how a facility detects intakes, quantifies them, and assigns defensible committed dose. ^{1, 2}

The physics is unforgiving in one specific way: a program whose minimum detectable activity sits above the dose of concern cannot prove anything with a "not detected" result. Getting the MDA, the calibration, and the dose-assessment chain right is therefore not paperwork; it is what makes the monitoring real. A facility that designs its counting time, shielding, and detector to the dose it needs to detect — and documents the full chain from counts to committed dose — has a program that protects workers and stands up to inspection.

How DRPS Can Help

Diagnostic Radiation Physics Services helps facilities design and defend internal-dosimetry and bioassay programs: setting monitoring thresholds, specifying counting frequency and MDA targets, reviewing thyroid and whole-body counting procedures, and documenting the dose-assessment chain. This work is part of our radiation safety officer consulting, radioactive material license support, and radiation safety training services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A bioassay program is only as strong as its least-sensitive measurement — so design it to detect the dose you actually care about.

Related Resources

References

National Council on Radiation Protection and Measurements. NCRP Report No. 87: Use of Bioassay Procedures for Assessment of Internal Radionuclide Deposition. NCRP; 1987. ncrponline.org
Health Physics Society / American National Standards Institute. ANSI/HPS N13.30-2011 (R2017): Performance Criteria for Radiobioassay. Health Physics Society. hps.org
U.S. Nuclear Regulatory Commission. 10 CFR 20.1502: Conditions Requiring Individual Monitoring of External and Internal Occupational Dose. ecfr.gov
International Commission on Radiological Protection. ICRP Publication 130: Occupational Intakes of Radionuclides — Part 1. Annals of the ICRP. 2015;44(2). icrp.org
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.9, Revision 1: Acceptable Concepts, Models, Equations, and Assumptions for a Bioassay Program. nrc.gov
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.20, Revision 1: Applications of Bioassay for I-125 and I-131. nrc.gov
Currie LA. Limits for qualitative detection and quantitative determination: application to radiochemistry. Analytical Chemistry. 1968;40(3):586-593. doi:10.1021/ac60259a007. doi.org
Dantas BM, Lucena EA, Dantas ALA, et al. A mobile bioassay laboratory for the assessment of internal doses based on in vivo and in vitro measurements. Health Phys. 2010;99(4):449-452. doi:10.1097/HP.0b013e3181c03e41. PubMed
Navarro JF, López MA, Navarro T, Gomez Ros JM, Moraleda M. Assessment of the internal dose of Am-241 in bone by in vivo measurements of activity deposited in knee. Radiat Prot Dosimetry. 2007;127(1-4):531-534. doi:10.1093/rpd/ncm411. PubMed
International Commission on Radiological Protection. ICRP Publication 119: Compendium of Dose Coefficients based on ICRP Publication 60. Annals of the ICRP. 2012;41(Suppl). icrp.org